Halozyme Enters Global Exclusive Collaboration with Oruka
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2026
0mins
Halozyme (HALO) and Oruka Therapeutics (ORKA) announced that Halozyme's wholly-owned subsidiary, Halozyme Hypercon, has entered into a global exclusive collaboration and license agreement with Oruka. Oruka has licensed Halozyme's Hypercon technology for use with ORKA-001, in development for psoriasis and related inflammatory diseases, and up to one additional target. Hypercon is an innovative microparticle technology that allows for hyperconcentration of drugs and biologics, reducing injection volume for a given dose and supporting more convenient, patient-friendly administration. Under the terms of the agreement, Oruka will make an upfront payment to Halozyme and potential future milestone payments. Halozyme will also be eligible to receive mid-single digit royalties on net sales of products developed using the Hypercon technology.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HALO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HALO
Wall Street analysts forecast HALO stock price to rise
5 Analyst Rating
3 Buy
1 Hold
1 Sell
Moderate Buy
Current: 68.570
Low
56.00
Averages
78.50
High
90.00
Current: 68.570
Low
56.00
Averages
78.50
High
90.00
About HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Halozyme Expects Minimal Impact from Medicare Drug Price Negotiation
- Royalty Revenue Outlook: Halozyme anticipates zero to minimal impact on its royalty revenues through 2035 based on its analysis of the Medicare Drug Price Negotiation Program, indicating strong confidence in the stability and predictability of future income.
- ENHANZE® Partnership Agreements: The company asserts that the drug price negotiations will not affect its ability to enter into new ENHANZE® partnership agreements, which not only ensures its market competitiveness but also continues to enhance patient treatment experiences.
- Innovation Protection Policies: The proposed rule affirms that orphan drug protections remain applicable, providing assurance for Halozyme's innovative products and ensuring competitive advantages amid the entry of biosimilars into the market.
- Technology Expansion Plans: Halozyme plans to expand its drug delivery technology portfolio through Hypercon™ and Surf Bio's technologies, which will enhance its capabilities in drug concentration and delivery, thereby strengthening its market position in the biopharmaceutical sector.
See More
Halozyme Anticipates Minimal Impact from Medicare Drug Price Negotiation
- Revenue Impact Assessment: Halozyme expects zero to minimal impact on its royalty revenues through 2035 based on an analysis of the proposed Medicare Drug Price Negotiation Program by CMS, indicating the company's resilience amid regulatory changes.
- Partnership Agreement Stability: The company asserts that the drug price negotiations will not affect its ability to execute new ENHANZE® partnership agreements, demonstrating a solid strategic focus on enhancing patient treatment experiences and competitive differentiation.
- Technology Innovation Expansion: Halozyme has expanded its drug delivery technology portfolio with Hypercon™ and Surf Bio's technology, which is expected to set a new standard in drug hyperconcentration by reducing injection volume, thereby facilitating more convenient drug administration in both home and healthcare settings, enhancing market competitiveness.
- Patient Experience Enhancement: The company's advanced auto-injector technologies aim to improve patient convenience and comfort, with existing commercial products like Hylenex® and XYOSTED® already achieving market success, reflecting Halozyme's ongoing commitment to enhancing patient adherence to treatment.
See More
Johnson & Johnson's Talvey Therapy Significantly Reduces Mortality Risk in Multiple Myeloma
- Clinical Trial Results: Johnson & Johnson's bispecific T-cell engager Talvey, in combination with Halozyme's Darzalex Faspro, demonstrated a mortality risk reduction of up to 53% in late-stage multiple myeloma trials, highlighting its therapeutic potential.
- Survival Rate Improvement: With a median follow-up of two years, approximately 89% of patients treated with Talvey plus Darzalex Faspro were alive at 24 months, compared to 79% in the standard treatment group, indicating a significant advantage in patient survival.
- Progression-Free Survival: The combination therapy achieved an 81% progression-free survival (PFS) rate, while the standard treatment group only reached 51%, showcasing the new therapy's effectiveness in delaying disease progression.
- Label Expansion Application: Johnson & Johnson has sought label expansions for Talvey plus Darzalex Faspro in the U.S. and EU, targeting relapsed/refractory multiple myeloma patients who have previously received at least one line of therapy, further enhancing market potential.
See More
Halozyme Reports Strong Q1 2026 Earnings and Strategic Outlook
- Strong Financial Performance: Halozyme reported total revenue of $377 million for Q1 2026, a 42% year-over-year increase, with royalty revenues reaching $241 million, up 43%, indicating sustained market demand for its ENHANZE portfolio and bolstering confidence in future profitability.
- Capital Return Plan: The company announced a new $1 billion share buyback authorization, expecting to repurchase at least $400 million of shares in 2026, a move that not only enhances shareholder value but also reflects management's confidence in the company's financial health, projecting net leverage to drop to approximately 1.2x by the end of 2026.
- Long-Term Profitability Goals: Management reaffirmed that adjusted EBITDA margins will exceed 65% during the 2026 to 2028 period, with expectations for ENHANZE royalties to surpass $1 billion for the first time in 2026, laying a solid foundation for future growth.
- Clinical Progress Adjustment: The timeline for Hypercon's Phase I clinical trial starts has been shifted from late 2026 to the first half of 2027, which may temporarily impact investor confidence but reflects the company's cautious approach to ensuring product quality and manufacturing capabilities.
See More
Halozyme (HALO) Q1 2026 Earnings Transcript
See More
FDA Approves Label Expansion for Vyvgart in Myasthenia Gravis
- Label Expansion Approval: The FDA has approved the label expansion for Vyvgart and Vyvgart Hytrulo in myasthenia gravis, allowing a broader section of adults to receive this therapy, which is expected to significantly enhance market coverage and sales.
- Strong Sales Performance: Argenx reported over $4 billion in global sales last year, indicating Vyvgart's robust market performance, and this label expansion is likely to further drive sales growth and solidify its market leadership.
- Clinical Research Support: The label expansion is backed by the results of the Phase 3 ADAPT SERON study, demonstrating Vyvgart's efficacy for all serotypes of myasthenia gravis patients, which bolstered the FDA's confidence in the approval.
- Collaborative Development Advantage: Vyvgart Hytrulo, the injectable version developed in partnership with Halozyme, leverages Halozyme's technological advantages, which is expected to enhance patient convenience and adherence, further expanding market potential.
See More
Halozyme Expects Minimal Impact from Medicare Drug Price Negotiation
- Royalty Revenue Outlook: Halozyme anticipates zero to minimal impact on its royalty revenues through 2035 based on its analysis of the Medicare Drug Price Negotiation Program, indicating strong confidence in the stability and predictability of future income.
- ENHANZE® Partnership Agreements: The company asserts that the drug price negotiations will not affect its ability to enter into new ENHANZE® partnership agreements, which not only ensures its market competitiveness but also continues to enhance patient treatment experiences.
- Innovation Protection Policies: The proposed rule affirms that orphan drug protections remain applicable, providing assurance for Halozyme's innovative products and ensuring competitive advantages amid the entry of biosimilars into the market.
- Technology Expansion Plans: Halozyme plans to expand its drug delivery technology portfolio through Hypercon™ and Surf Bio's technologies, which will enhance its capabilities in drug concentration and delivery, thereby strengthening its market position in the biopharmaceutical sector.
See More
Halozyme Anticipates Minimal Impact from Medicare Drug Price Negotiation
- Revenue Impact Assessment: Halozyme expects zero to minimal impact on its royalty revenues through 2035 based on an analysis of the proposed Medicare Drug Price Negotiation Program by CMS, indicating the company's resilience amid regulatory changes.
- Partnership Agreement Stability: The company asserts that the drug price negotiations will not affect its ability to execute new ENHANZE® partnership agreements, demonstrating a solid strategic focus on enhancing patient treatment experiences and competitive differentiation.
- Technology Innovation Expansion: Halozyme has expanded its drug delivery technology portfolio with Hypercon™ and Surf Bio's technology, which is expected to set a new standard in drug hyperconcentration by reducing injection volume, thereby facilitating more convenient drug administration in both home and healthcare settings, enhancing market competitiveness.
- Patient Experience Enhancement: The company's advanced auto-injector technologies aim to improve patient convenience and comfort, with existing commercial products like Hylenex® and XYOSTED® already achieving market success, reflecting Halozyme's ongoing commitment to enhancing patient adherence to treatment.
See More
Johnson & Johnson's Talvey Therapy Significantly Reduces Mortality Risk in Multiple Myeloma
- Clinical Trial Results: Johnson & Johnson's bispecific T-cell engager Talvey, in combination with Halozyme's Darzalex Faspro, demonstrated a mortality risk reduction of up to 53% in late-stage multiple myeloma trials, highlighting its therapeutic potential.
- Survival Rate Improvement: With a median follow-up of two years, approximately 89% of patients treated with Talvey plus Darzalex Faspro were alive at 24 months, compared to 79% in the standard treatment group, indicating a significant advantage in patient survival.
- Progression-Free Survival: The combination therapy achieved an 81% progression-free survival (PFS) rate, while the standard treatment group only reached 51%, showcasing the new therapy's effectiveness in delaying disease progression.
- Label Expansion Application: Johnson & Johnson has sought label expansions for Talvey plus Darzalex Faspro in the U.S. and EU, targeting relapsed/refractory multiple myeloma patients who have previously received at least one line of therapy, further enhancing market potential.
See More
Halozyme Reports Strong Q1 2026 Earnings and Strategic Outlook
- Strong Financial Performance: Halozyme reported total revenue of $377 million for Q1 2026, a 42% year-over-year increase, with royalty revenues reaching $241 million, up 43%, indicating sustained market demand for its ENHANZE portfolio and bolstering confidence in future profitability.
- Capital Return Plan: The company announced a new $1 billion share buyback authorization, expecting to repurchase at least $400 million of shares in 2026, a move that not only enhances shareholder value but also reflects management's confidence in the company's financial health, projecting net leverage to drop to approximately 1.2x by the end of 2026.
- Long-Term Profitability Goals: Management reaffirmed that adjusted EBITDA margins will exceed 65% during the 2026 to 2028 period, with expectations for ENHANZE royalties to surpass $1 billion for the first time in 2026, laying a solid foundation for future growth.
- Clinical Progress Adjustment: The timeline for Hypercon's Phase I clinical trial starts has been shifted from late 2026 to the first half of 2027, which may temporarily impact investor confidence but reflects the company's cautious approach to ensuring product quality and manufacturing capabilities.
See More
Halozyme (HALO) Q1 2026 Earnings Transcript
See More
FDA Approves Label Expansion for Vyvgart in Myasthenia Gravis
- Label Expansion Approval: The FDA has approved the label expansion for Vyvgart and Vyvgart Hytrulo in myasthenia gravis, allowing a broader section of adults to receive this therapy, which is expected to significantly enhance market coverage and sales.
- Strong Sales Performance: Argenx reported over $4 billion in global sales last year, indicating Vyvgart's robust market performance, and this label expansion is likely to further drive sales growth and solidify its market leadership.
- Clinical Research Support: The label expansion is backed by the results of the Phase 3 ADAPT SERON study, demonstrating Vyvgart's efficacy for all serotypes of myasthenia gravis patients, which bolstered the FDA's confidence in the approval.
- Collaborative Development Advantage: Vyvgart Hytrulo, the injectable version developed in partnership with Halozyme, leverages Halozyme's technological advantages, which is expected to enhance patient convenience and adherence, further expanding market potential.
See More
